Second clot-dissolving dose for stroke that doesn't improve
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial studies whether giving a second dose of a clot-busting medicine (tenecteplase) is safe for people having a severe stroke who did not improve after the first dose. It aims to help dissolve the clot better and improve recovery without causing harmful bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be having stroke symptoms that started less than 3 hours ago (to get the first dose).
- You must be between 18 and 80 years old.
- The stroke must be severe enough (based on a standard exam) to qualify for this extra dose.
- A CT scan of your head must not show bleeding, and it must look like there is still a good amount of healthy brain tissue.
- You must not have a large blocked vessel that requires a mechanical clot-removal procedure.
- You must not be on blood thinners or have other conditions that raise the risk of bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a stronger clot-busting drug (tenecteplase) is safe and works for people who have had a stroke while taking a common blood thinner. If you qualify, you may get this treatment within a few hours of your stroke to help improve recovery.
This trial tests whether a clot-dissolving drug called tenecteplase can improve recovery for people who had a large-vessel ischemic stroke 4.5 to 24 hours earlier and can’t have a mechanical clot removal procedure in time. If you join, you’ll get either tenecteplase or standard medical care, and the study will track your recovery and safety.
This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
This trial tests giving a second dose of an IV clot-dissolving medicine (prourokinase) to patients who had a stroke from a large clot but didn't improve enough after the first dose. The goal is to see if a second dose within 6 hours of stroke onset can help more patients recover.
This trial tests a clot-busting drug called tenecteplase given later than usual (4.5 to 9 hours after stroke symptoms) to people whose MRI shows the stroke may still be reversible. The goal is to see if it helps reduce disability after a stroke.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.